论文部分内容阅读
干细胞有无限制自我更新以及分化成多种祖细胞的能力。间充质干细胞(MSCs)能特异地向多种肿瘤以及它们的转移灶迁移,并且它们的迁移是遍及全身的。借助这一特性,基因修饰MSCs可用作特异性靶向药物的载体并表达抗癌因子以抑制肿瘤生长。然而,许多问题和确切的机制尚待解答。本文主要回顾MSCs归巢的机制、MSCs作为载体用于肿瘤治疗以及MSCs与无活性药物载体相比的优缺点。MSCs作为载体可能成为一种细胞治疗,在未来的肿瘤治疗中发挥作用。
Stem cells have the ability to limit self-renewal and differentiate into multiple progenitor cells. Mesenchymal stem cells (MSCs) specifically migrate to a variety of tumors and their metastases, and their migration is pervasive. With this feature, genetically modified MSCs can serve as a carrier for specific targeting drugs and express anti-cancer factors to inhibit tumor growth. However, many questions and exact mechanisms remain to be answered. This article reviews mainly the mechanism of homing of MSCs, the advantages and disadvantages of using MSCs as carriers for tumor therapy and MSCs versus inactive drug carriers. MSCs as a carrier may become a cell therapy, play a role in the future of cancer treatment.